Traduction de «disease a meta-analysis » (Néerlandais → Français) :

Table 1: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.
Table 3: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.

Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and bupropion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.
Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and Buproprion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.

Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

Kim C et al - Am.Heart J. 44 2001 meta analysis yes 82 studies Coronary disease diagnostic : maximum sensitivity with vasodilatator combined with SPECT, maximum specificity with vasodilatator combined with DSE.
Kim C et al - Am.Heart J. 46 2001 meta analysis yes 82 studies Coronary disease diagnostic : maximum sensitivity with vasodilatator combined with SPECT, maximum specificity with vasodilatator combined with DSE.

44. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis.
46. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis.

Berger JS, Kranz MJ, Kittelson JM et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A meta-analysis of randomized trials.
Fowkes FG, Price JF, Stewart MCW et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

DOI: 10.1002/14651858.CD000254.pub3. Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.
Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

(Schürks 2009) Schürks M, Rist PM, Bigal ME et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ
(Schürks 2009) Schürks M, Rist PM, Bigal ME et al. Migraine and cardiovascular disease: systematic review and meta-analysis.

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Tabel 1: Daling van de specifieke sterfte bij vrouwen van 40 tot 49 jaar Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 1: Réduction de la mortalité spécifique Study ID Ref Population Intervention Results of